The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever
暂无分享,去创建一个
G. Gutiérrez-García | M. Díaz-Ricart | M. Lozano | J. Cid | C. Martínez | J. Bladé | M. Palomo | L. Rosiñol | M. Cibeira | Á. Urbano-Ispizua | C. Fernández de Larrea | Alexandra Martínez-Roca | L. Rodríguez-Lobato | C. Gallego | F. Fernández-Avilés | M. Suárez-Lledó | M. Rovira | A. Moreno-Castaño | P. Marín | E. Carreras | Sandra Castaño-Díez | S. Segura | E. Lozano | A. Pedraza | A. Hernando | Alicia Palomino-Mosquera | A. Martínez-Roca | S. Castaño-Díez | Adelina Hernando | A. B. Moreno-Castaño | Cristina Gallego
[1] G. Gutiérrez-García,et al. Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients , 2020, Leukemia & lymphoma.
[2] G. Gutiérrez-García,et al. A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe , 2020, Bone Marrow Transplantation.
[3] María Teresa Solano,et al. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis , 2019, Bone Marrow Transplantation.
[4] G. Gutiérrez-García,et al. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation , 2018, Bone Marrow Transplantation.
[5] R. Greil,et al. The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe , 2018, Expert review of hematology.
[6] H. Goldschmidt,et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] H. Goldschmidt,et al. High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting , 2017, BMC Cancer.
[8] D. Giannarelli,et al. Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study , 2017, Bone Marrow Transplantation.
[9] L. Castagna,et al. Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma , 2016, Bone Marrow Transplantation.
[10] G. Gutiérrez-García,et al. At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study , 2016, Bone Marrow Transplantation.
[11] P. Hari,et al. Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] S. Crawford,et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] T. Walsh,et al. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] D. Porter,et al. Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. , 2015, Clinical lymphoma, myeloma & leukemia.
[15] A. Gennery,et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015 , 2015, Bone Marrow Transplantation.
[16] P. Hari,et al. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma , 2015, Bone Marrow Transplantation.
[17] M. Postorino,et al. A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study , 2015, Leukemia & lymphoma.
[18] R. Gale,et al. Engraftment syndrome, the Emperor’s new clothes and the artist formerly known as prince , 2015, Bone Marrow Transplantation.
[19] T. Spitzer,et al. Engraftment syndrome: double-edged sword of hematopoietic cell transplants , 2015, Bone Marrow Transplantation.
[20] A. López-Guillermo,et al. Survival analysis in hematologic malignancies: recommendations for clinicians , 2014, Haematologica.
[21] M. Dimopoulos,et al. International Myeloma Working Group recommendations for global myeloma care , 2014, Leukemia.
[22] H. Heslop,et al. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma , 2013, Bone Marrow Transplantation.
[23] M. Sanz,et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients , 2014, Annals of Hematology.
[24] P. Hari,et al. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] Stephanie J. Lee,et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[26] G. Sauvageau,et al. Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[27] W. Dempke,et al. Multiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy: a meta-analysis. , 2012, Anticancer research.
[28] B. Esterni,et al. Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs , 2012, Bone Marrow Transplantation.
[29] M. Díaz-Ricart,et al. Combining allografting with mTOR inhibitors for metastatic renal cell cancer , 2011, Bone Marrow Transplantation.
[30] D. Dingli,et al. SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization , 2011, Bone Marrow Transplantation.
[31] K. Sepkowitz,et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] M. Dimopoulos,et al. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem‐cell transplantation: Results of a single institution, randomized phase 2 trial , 2010, American journal of hematology.
[33] F. Aversa,et al. Regression modeling of competing risk using R: an in depth guide for clinicians , 2010, Bone Marrow Transplantation.
[34] M. Díaz-Ricart,et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[35] M. Lozano,et al. Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center , 2010, Bone Marrow Transplantation.
[36] Hermann Einsele,et al. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective , 2009, Biology of Blood and Marrow Transplantation.
[37] M. Díaz-Ricart,et al. The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[38] D. Dingli,et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome , 2008, European journal of haematology.
[39] F. Aversa,et al. Competing risk analysis using R: an easy guide for clinicians , 2007, Bone Marrow Transplantation.
[40] E. Montserrat,et al. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] C. Solano,et al. Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fluoroquinolones and intravenous piperacillin–tazobactam , 2005, Bone Marrow Transplantation.
[42] L. Rybicki,et al. Steroids prevent engraftment syndrome after autologous hematopoietic stem cell transplantation without increasing the risk of infection , 2005, Bone Marrow Transplantation.
[43] Â. Maiolino,et al. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria , 2003, Bone Marrow Transplantation.
[44] P. Mcsweeney,et al. High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[45] T. Spitzer. Engraftment syndrome following hematopoietic stem cell transplantation , 2001, Bone Marrow Transplantation.